TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
Poster: Primary MR in the Very Elderly
bRIGHT 2-year real-world outcomes
Prognosis of TR after MitraClip for MR
PCR LV 2021: Navitor™ Live-in-a-box
bRIGHT study
Navitor Valve in small aortic annuli
ESOC presentation: PFO closure in patients > 60 Years
2-year outcomes from the TRILUMINATE Pivotal trial
ACC 2023: COAPT™ trial
TRENDING TOPICS
Poster: Primary MR in the Very Elderly
Prognosis of TR after MitraClip for MR
bRIGHT 2-year real-world outcomes
